In vitro detection of circulating tumor cells compared by the CytoTrack and CellSearch methods

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4597-4601

  Hillig, Thore ^a   Horn, Peer ^b   Nygaard, Ann Britt ^a   Haugaard, Anastasiya S ^a   Nejlund, Sarah ^a   Brandslund, Ivan ^b   Sölétormos, György ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

Author keywords

CellSearch; CTC; CytoTrack; Enumeration; Recovery

Indexed keywords

CYTOKERATIN; PANCYTOKERATIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; KERATIN; TUMOR ANTIGEN; TUMOR MARKER;

ANTIBODY SPECIFICITY; ARTICLE; BLOOD DONOR; BREAST CANCER; CELL ADHESION; CELL CULTURE EQUIPMENT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; MCF 7 CELL LINE; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR EMBOLISM;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL ADHESION MOLECULES; FEMALE; HUMANS; IN VITRO TECHNIQUES; KERATINS; MCF-7 CELLS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS;

EID: 84938970058     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3105-z     Document Type: Article

References (18)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
2. Parkinson DR, Dracopoli N, Gumbs Petty B, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012;10:138.
3. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013;32:179–88.
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
5. Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol. 2011;122:567–72.
6. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.
7. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:1136–42.
8. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24.
9. Hillig T, Nygaard AB, Nekiunaite L, Klingelhofer J, Soletormos G. In vitro validation of an ultra-sensitive scanning fluorescence microscope for analysis of circulating tumor cells. APMIS. 2014;122:545–51.
10. Gerges N, Rak J, Jabado N. New technologies for the detection of circulating tumour cells. Br Med Bull. 2010;94:49–64.
11. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920–8.
12. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57:1242–55.
13. D’Agostino R, Pearson ES. Tests of departure from normality. Empirical results for the distribution of b2 and √b1. Biometrika. 1973;60:613–22.
14. NORIP N. NORIP reference value for leukocytes. 2014:http://pweb.furst.no/norip/hem/Lkc.pdf.
15. Veridex L. CellSearchTM Circulating Tumor Cell Kit, patent found at http://www.accessdata.fda.gov/cdrh_docs/pdf7/K073338.pdf. 2008.
16. Langkjer ST. Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer (XeNa). ClinicalTrials.gov Identifier: NCT01941771. https://clinicaltrials.gov/ct2/show/NCT01941771?term=XeNa&rank=1.
17. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11:R46.
18. Gorges TM, Tinhofer I, Drosch M, Rose L, Zollner TM, Krahn T et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012;12:178,2407-12-178